NSAID PRIOR AUTHORIZATION IS COST EFFECTIVE, AHCPR-FUNDED STUDY OF TENNESSEE MEDICAID CONCLUDES; COMPUTER-BASED DUR SHOULD BE VALIDATED -- NEJM ARTICLE
Prior authorization is a cost-effective strategy for managing use of nonsteroidal anti-inflammatory drugs, an AHCPR-funded study published in the New England Journal of Medicine June 15 concludes.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth